Breakthrough biomaterial heals tissue from the inside out

In the field of regenerative medicine, a significant challenge has always been the delivery of therapeutic agents to fragile or difficult-to-access organs. Traditionally, repairing a heart after a myocardial infarction (heart attack) required direct needle injections into the cardiac muscle—a procedure that is not only invasive but carries the risk of further injuring already compromised tissue. However, a breakthrough biomaterial developed by bioengineers at the University of California San Diego is shifting the paradigm toward treating damaged organs “from the inside out.”

Harnessing the Bloodstream for Targeted Repair

The innovation centers on a biomaterial derived from the decellularized extracellular matrix (ECM) of cardiac tissue. Unlike previous hydrogels that were too viscous for systemic delivery, this new iteration is processed into nano-sized particles. These particles are small enough to be delivered via a standard intravenous (IV) infusion or through a coronary artery during routine procedures like angioplasty.

Once in the bloodstream, the biomaterial utilizes the body’s natural response to injury. Following a heart attack or traumatic injury, blood vessels become “leaky,” developing gaps between endothelial cells. The biomaterial is engineered to localize specifically at these sites, binding to the damaged vessel walls.

Mechanisms of Action: Inflammation and Structural Integrity

Preclinical studies in both rodent and porcine models have demonstrated that the biomaterial does more than just fill gaps. Upon binding to the leaky microvasculature, it effectively “plasters” the internal lining of the vessels, reducing the damaging inflammation that typically follows acute injury. By stabilizing the vascular barrier, the material encourages a pro-repair environment, limiting the formation of non-contractile scar tissue and improving overall heart function.

Broad Clinical Implications

While the primary focus has been cardiac recovery, the “inside out” approach holds potential for any condition driven by vascular inflammation. Early proof-of-concept experiments suggest efficacy in treating traumatic brain injury (TBI) and pulmonary arterial hypertension, where direct tissue access is similarly restricted.

As of 2026, research continues to refine these therapies, with spatial transcriptomics revealing that these ECM-based materials trigger complex immune modulation and neurogenesis. As clinical trials progress, this IV-delivered biomaterial represents a major leap toward making regenerative engineering as simple and accessible as a standard infusion.

Read the full article on Sciencedaily.com